Mark
Managing director
Pharmaceutical Sciences
Bristol-myers Sqibb
Georgia
Biography
Mark’s team is responsible for exploring and validating new targets and developing fully human antibodies for clinical evaluation in oncology. The targets of interest are those that promote immune suppressive tumor environments and include, but are not limited to, positive and negative co-stimulators. Mark also directly supervises four Ph.D. scientists who are working on multiple antibody programs in both early and late stage development.
Research Interest
Pharmaceutical Sciences
